Sertralina versus trimebutina en el tratamiento del Síndrome de intestino irritable: una revisión sistemática

Abstract

“SERTRALINE VERSUS TRIMEBUTINE IN THE TREATMENT OF IRRITABLE BOWEL SYNDROME: A SYSTEMATIC REVIEW” Objective: This systematic review aimed to compare the efficacy of sertraline versus trimebutine in the treatment of irritable bowel syndrome (IBS), considering both digestive symptoms and the presence of emotional comorbidities. Methodology: Open-access articles published in Spanish or English within the last decade, that included an adult population aged 18 years or older, were selected. Clinical trials and observational studies were considered, excluding reviews and case reports. The databases Scopus, PubMed, Taylor & Francis, Cochrane, ProQuest, Web of Science, and Springer Nature were used in a search period from November 2024 to April 2025. The risk of bias was assessed using the RoB 2 tool for clinical studies and the JBI Critical Appraisal Tools for observational studies and narrative reviews. The results were synthesized descriptively using tables and figures. Results: Nine articles were analyzed. Trimebutine demonstrated moderate efficacy in alleviating digestive symptoms, particularly when combined with other treatments. In contrast, sertraline offered better results in patients with IBS associated with anxiety or depression, although a possible increased risk of microscopic colitis was observed. Discussion: The identified limitations include methodological heterogeneity and limited access to certain studies. Conclusions: Trimebutine is adequate in mild cases of IBS, while sertraline is preferable when there is emotional involvement. The importance of personalizing treatments and promoting higher-quality research is emphasized.